

Serial No. 09/825,144

- 2 -

Art Unit 1644

74.(new) The method of claim 4, wherein the Fyb/SLAP complex inhibitor is selected from the group consisting of ActA repeats, EVH1 binding peptides, ScarWA, and dominant negative Fyb/SLAP fragments.

75.(new) The method of claim 1, wherein the cell is a lymphocyte or a macrophage.

76.(new) The method of claim 75, wherein the lymphocyte is a T cell.

77.(new) The method of claim 1, wherein the cell fragment is a platelet.

78.(new) The method of claim 30, wherein the Ena/VASP family protein is selected from the group consisting of Ena, Mena, VASP and Evl.

79.(new) The method of claim 30, wherein the Fyb/SLAP complex inhibitor comprises the peptide FPPPP (SEQ ID NO:15) or a peptide mimetic having an equivalent binding specificity.

80.(new) The method of claim 79, wherein the Fyb/SLAP complex inhibitor is selected from the group consisting of ActA repeats, EVH1 binding peptides, ScarWA, and dominant negative Fyb/SLAP fragments.

81.(new) The method of claim 42, wherein the Ena/VASP family protein is selected from the group consisting of Ena, Mena, VASP and Evl.

82.(new) The method of claim 42, wherein the Fyb/SLAP complex inhibitor comprises the peptide FPPPP (SEQ ID NO:15) or a peptide mimetic having an equivalent binding specificity.

83.(new) The method of claim 82, wherein the Fyb/SLAP complex inhibitor is selected from the group consisting of ActA repeats, EVH1 binding peptides, ScarWA, and dominant negative Fyb/SLAP fragments.